Comparative Pharmacology
Head-to-head clinical analysis: DROSPIRENONE versus MEGACE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DROSPIRENONE versus MEGACE.
DROSPIRENONE vs MEGACE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Spironolactone analog that antagonizes aldosterone at the mineralocorticoid receptor, leading to increased sodium and water excretion and potassium retention. Also has antiandrogenic activity by blocking androgen receptors and decreasing ovarian androgen production via inhibition of gonadotropin release.
Megestrol acetate is a synthetic progestin that inhibits pituitary gonadotropin secretion, leading to suppression of ovarian function and reduction of sex hormone levels. It also has antineoplastic effects through interference with estrogen receptor binding and may stimulate appetite via effects on neuropeptide Y and cytokines.
3 mg orally once daily.
Oral: 625 mg (suspension) or 400–800 mg (tablets) once daily.
None Documented
None Documented
Clinical Note
moderateDrospirenone + Benzydamine
"Drospirenone may increase the hyperkalemic activities of Benzydamine."
Clinical Note
moderateDrospirenone + Droxicam
"Drospirenone may increase the hyperkalemic activities of Droxicam."
Clinical Note
moderateDrospirenone + Loxoprofen
"Drospirenone may increase the hyperkalemic activities of Loxoprofen."
Clinical Note
moderateDrospirenone + Clonixin
"Drospirenone may increase the hyperkalemic activities of Clonixin."
Terminal elimination half-life: ~30-35 hours (range 25-40 h); significant clinical accumulation occurs after repeated dosing, requiring 10-14 days to reach steady state.
Terminal elimination half-life: 70-95 hours (mean 85 hours) in chronic dosing; shorter in initial doses; clinical context: requires 3-4 weeks to reach steady state.
Renal: ~50% (as metabolites; <10% unchanged); Fecal: ~40-50% (as metabolites; bile-mediated); Urinary and fecal elimination account for >95% of an oral dose.
Primarily renal: ~75% as glucuronide conjugates and unchanged drug; biliary/fecal: ~25% as metabolites.
Category C
Category C
Progestin
Progestin